<DOC>
	<DOCNO>NCT00912301</DOCNO>
	<brief_summary>The study hypothesis naturally occur bile acid , chenodeoxycholic acid , induces acceleration colonic transit health patient constipation-predominant Irritable Bowel Syndrome ( IBS-C ) .</brief_summary>
	<brief_title>Cheno Effect Transit Health IBS-C</brief_title>
	<detailed_description>Hypothesis : A hydrophobic di-alpha hydroxy bile salt , sodium chenodeoxycholate ( CDC ) , deliver delayed release capsule ileocolonic region colon induces acceleration colonic transit patient constipation-predominant IBS . Methods : We shall study 36 patient IBS-C , age 18-65 year , treatment group balance gender Body Mass Index ( BMI ) randomization . All patient assess symptom functional gastrointestinal disorder psychological disturbance characterize standard fashion questionnaire ( Talley et al 1989 ) , Psychosomatic Symptom Checklist ( SCL-90 ) Hospital Anxiety Depression Inventory [ HAD ( Zigmond Snaith 1983 ) ] . With appropriate consent , venous blood sample obtain participant DNA extraction . Fasting Serum 7alpha-hydroxy-4-cholesten-3-one ( 7alpha-CHO ) measure ensure evidence asymptomatic bile acid malabsorption . The normal range lab &lt; 61 ng/mL . Experimental design : A randomized , double blind , placebo control , dose-response parallel group design , conceal allocation . Participants undergo initial baseline colonic transit 24 hour obtain Colonic Geometric Center ( GC24 ) . Sodium chenodeoxycholate ( CDC ) deliver ileocolonic region ass ascend colon whole colonic transit participant IBS-C ; 12 participant per group randomize placebo , 0.5 1 gram CDC period 4 day transit study conduct last 48 hour drug ingestion . The CDC place gelatin capsule coat methacrylate ( EUDRAGIT-LÂ® ) , pH-sensitive polymer result release active ingredient terminal ileum . Experimental procedure : At standardize time ( hourly first 8 hour , 12 , 24 48 h ) , dual gamma camera scan obtain measure ascend colon overall colonic transit . Patients fill daily diary evaluate stool , frequency , consistency ease passage . Gastrointestinal Colonic Transit : A validated scintigraphic method measure gastric , small bowel , colonic transit use . A methacrylate-coated capsule dissolve alkaline pH distal ileum release 111In-labeled activated charcoal particle evaluate colonic transit sequential scan . Meanwhile , orally ingest 99 mTc-labeled egg meal allow measurement gastric small bowel transit . ( Technetium [ 99mTc ] sestamibi ( trade name Cardiolite ) pharmaceutical agent use nuclear medicine imaging . ) We previously show gastric emptying ( GE ) 2 4 hour , colonic filling ( CF ) 6 hour , colonic geometric center ( GC , weight average isotopic count ) colon 4 , 24 48 hour provide excellent summary gastric empty colonic transit similar diagnostic accuracy detail , costly , time-consuming analysis . The normal value parameter previously publish ( Cremonini et al ) . Scintigraphic gastric empty intestinal/colonic transit analysis : A variable region interest program use measure transit , previous study lab . Radioisotope content region ( gastric , ascend , transverse , descend , rectosigmoid ) correct decay tissue attenuation depth . Anticipated Result : CDC accelerate whole colonic transit loosen stool form patient constipation predominant IBS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Chenodeoxycholic Acid</mesh_term>
	<criteria>Healthy volunteer : Age ( yr ) 1865 Gender ( F : M ) 3.5 :1 Bowel Disease Questionnaire ( BDQ ) IBS symptom negative Rome III criterion Hospital Anxiety/Depression score &lt; 8 IBS patient : Age ( yr ) 1865 Gender ( F : M ) 5 :1 BDQ IBS symptom : positive Rome III criterion Hospital Anxiety/Depression score : No restriction Abdominal surgery ( except appendectomy cholecystectomy ) GI medication 48h prior transit measurement Aspartate/Alanine transaminases &gt; 2 X Upper Limit Normal ( ULN ) Other Medications except stable dos estrogen , thyroid , low dose antidepressant dopaminergic serotonergic class</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>chenodeoxycholate , IBS , transit , colon , constipation</keyword>
</DOC>